In this episode, Ana Reisdorf, MS, RD, dietitian, GLP-1 patient, and founder of GLP-1 Hub, joins us to talk about building a space for people on GLP-1 medications
doi: 10.1111/ijpo.70024
* Correspondence: Xue Yang [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
These same strategies may be ineffective when elevated SAH, adenosine accumulation, toxic burden, creatine demand or impaired clearance is the main bottleneck
While this requirement may narrow some claims, it streamlines the litigation as the court prepares to address broader issues like federal preemption and general causation